Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 42INDUSTRY 8OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastric Adenocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Capecitabine 9Bevacizumab 8tislelizumab 7Oxaliplatin 7Drug Therapy 7pembrolizumab 6Surgical Procedures, Operative 6Cisplatin 6Standard of Care 5Radiotherapy 5Laparoscopy 5Fluorouracil 5Docetaxel 5Carboplatin 5toripalimab 4Radiosurgery 4Leucovorin 4Exercise 4Epirubicin 4Cyclophosphamide 4pertuzumab 3durvalumab 3dalpiciclib 3atezolizumab 3anlotinib 3Saline Solution 3Rituximab 3Radiation 3Prednisone 3Population Groups 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × apatinib × 1 year × Clear all
NCT07618546 2026-06-01

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Henan Cancer Hospital

Phase NA Not yet recruiting
208 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07610629 2026-05-28

RA-A-NP

Henan Cancer Hospital

Phase 2 Not yet recruiting
50 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡